MedTech companies in 2025 face a more complex commercialisation landscape than ever before. They grapple with fragmented regulations, intense competition from new entrants, and pricing pressures from cost-conscious health systems. Traditional go-to-market approaches are struggling to keep pace; market data often comes in silos or outdated reports, leaving teams reactive instead of proactive.